Showing results (371-380 of 753) with videos related to
Sort By:
Pageof 76
Neuro-Oncology|January 14, 2025
Benchmarking the Efficacy of Salvage Systemic Therapies for Recurrent Meningioma: A RANO Group Systematic Review and Meta-analysis to Guide Clinical Trial DesignRupesh Kotecha, Eyub Y Akdemir, Tugce Kutuk, et al.The Journal of Clinical Endocrinology and Metabolism|July 30, 2010
Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expressionZachary M Bush, Janina A Longtine, Tracy Cunningham, et al.Oncotarget|February 9, 2018
Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05)Lode J Swinnen, Anne O'Neill, Philip H Imus, et al.Molecular Cancer Therapeutics|February 5, 2009
Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapyYunqing Li, Fadila Guessous, Charles DiPierro, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphomaGaurav D Shah, Joachim Yahalom, Denise D Correa, et al.Cancer Research|March 15, 2008
PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutationsYunqing Li, Fadila Guessous, Sherwin Kwon, et al.Neuro-Oncology|May 29, 2015
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade gliomaPatrick Y Wen, Antonio Omuro, Manmeet S Ahluwalia, et al.The Lancet. Oncology|September 3, 2013
Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO groupNancy U Lin, Eudocia Q Lee, Hidefumi Aoyama, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendrogliomaRobert Brown, Magdalena Zlatescu, Angelique Sijben, et al.Journal of Neuro-Oncology|March 4, 2021
Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in GlioblastomaSohil H Patel, Prem P Batchala, Thomas J Eluvathingal Muttikkal, et al.Pageof 76